Sign in

NCT06017960Completed

Effects of Dry Needling on Electromyographic Activity and Ultrasonographic Characteristics in Post-Stroke Spasticity

Source: ClinicalTrials.gov · Last updated 14 Sept 2026

Brief summary (registry, in English)

Stroke is a global health problem, with an incidence in Europe of 147/100,000 people per year. It is estimated that 43% of them present spasticity throughout the first year, causing disability, hindering mobility and functionality, which can generate comorbidity problems, which in turn hinders its improvement over time. Recently, high quality studies have conclude that there is a moderate level of evidence with large effect size in reducing spasticity with dry needling, as well as being cost-effective in stroke patients in both the subacute and chronic phases. However, due to the limitation of manual evaluations of spasticity, and it is necessary to look for measurement alternatives that complement it, such as the analysis of the electromyographic activity and the muscular structure measured with ultrasound. These data could provide objective, useful and complementary information to clinical assessments to be more specific and effective in the treatment of stroke patients. This randomized controlled trial aim to analyse the effect of dry needling in this parameters in patients with stroke and spasticity, as well as correlated with gait variables. Each participant will be randomly assigned to the dry needling group or to the sham dry needling group, where participants receive a total of 4 sessions of ultrasound-guided dry needling or sham ultrasound-guided dry needling in the gastrocnemius medialis over 4 weeks, one per week. Measures of spasticity, electromyographic activity and muscle structure via ultrasound will made at baseline (T0) and immediate after each intervention (T1,T2,T3,T4). Gait variables will be made at baseline and after the last intervention (T0 and T4).

Status (registry)
Completed
Study type
Interventional
Enrollment
28 (actual)
First submitted
19 Aug 2023
Start date
15 Sept 2023
Primary completion date
11 Aug 2026
Lead sponsor
Universidad de Zaragoza
Diseases
Stroke
NCT number
NCT06017960

What you commit to

  • Study type: Interventional
  • Participants enrolled: 28
  • From 15 Sept 2023 to the primary completion date, 11 Aug 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • who have received previous treatments of botulinum toxin type A in the last 3 months
  • who have received treatments with dry needling in the last month

Other illness

  • recurrent stroke
  • metal allergy.

Other

  • severe cognitive deficits
  • fear of needles

Who the study is looking for

  • be over 18 years old
  • understand and voluntarily sign informed consent before performing the intervention
  • have a medical diagnosis of ischemic or hemorrhagic stroke
  • have a grade between 1-3 according to the modified Ashworth scale (MAS) on the triceps sural
  • able to walk independently to perform gait test

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centro Europeo de Neurociencias
Coordinator of this site? Confirm its status
MadridSpainUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.